

## Hetlioz Prior Auth Form Fax 1-866-423-0945 Pharmacy Dept. Phone 401-427-8200

This form is to be used by participating physicians and providers to obtain coverage. Please complete the form by providing all of the following information. Fax the completed form to Neighborhood at 1-866-423-0945. For real time Coverage Determination decisions, please go to Cover My Meds: <a href="https://www.covermymeds.com/epa/caremark/">https://www.covermymeds.com/epa/caremark/</a>.

Hetlioz (ta	asimelt	teon) Pr	io	or Auth	ıorizat	ion Form
Enrollee's Name					Date of Bir	th
Enrollee's Address						
City		State			Zip Code	
Phone		Enrollee <sup>3</sup>	's N	Member ID #	<del></del>	
	Impo	rtant Note: E	Zxp	edited Decis	sions	
If you or your prescriber or ability to regain maxim	um function,	you can ask fo	or a	n expedited (	(fast) decision	n.
		Prescriber's	In	formation		
Name and NPI						
Address						
City		State			Zip Code	
Office Phone			Fa	X		
Prescriber's Signature					Date	
	Diag	gnosis and Me	edio	cal Informa	tion	
Medication:		Strength and Route of Administration:				Frequency:
New Prescription OR De Initiated:	ate Therapy	Expected Length of Therapy:			Quantity:	
Height/Weight:	Drug Aller	gies:		Diagnosis:		

	Criteria Questions		
1	Does the member have a diagnosis of total blindness in both eyes (e.g., nonfunctioning retinas)?	Yes	N
	If yes, must attach supporting clinical documentation of diagnosis.		
2	Is the member able to perceive light in either eye?	Yes	N
3	Is the member experiencing difficulty initiating sleep, difficulty awakening in the morning, or excessive daytime sleepiness?	Yes	N
4	Does the member have a confirmed clinical diagnosis of Smith-Magenis syndrome with a history of sleep disturbances?	Yes	N
	If yes, must attach supporting clinical documentation of diagnosis.		
5	Is this for continuation of therapy?	Yes	N
	If yes, please supply date therapy initiated: If no, no further questions		
	For continuation in Non-24-Hour Sleep-Wake Disorder, has the member experienced an increase in total nighttime sleep and/or decreased daytime nap duration? [Submit clinical documentation]	Yes	N
	For continuation in sleep disturbances in Smith-Magenis Syndrome, has the member experienced an improvement in quality of sleep (e.g., improvement in sleep efficiency, sleep onset and final sleep offset, or waking after sleep onset)? [Submit clinical documentation]		